KRYSTAL-17: Adagrasib Combinations in Patients with KRAS G12C Mutation
Condition: Non-Small Cell Lung Cancer
Sponsor: Mirati Therapeutics, Inc.
Full Title
Protocol 849-017: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Study Treatment
KRAS G12C inhibitor adagrasib in combination with standard chemo/immunotherapy.
Eligibility/Info
Unresectable or metastatic KRAS G12C mutant non-squamous non-small cell lung cancer that has not been treated in the metastatic setting.
Contact
For more information about this or any other study, please contact the NYCBS Research Department:
Email: ResearchRecruitment@nycancer.com
Telephone: 631-675-5075
HALO Messaging App: "Research Team"
